Sparrow Plans Trial of SPI-62 in Cushing’s Syndrome

Sparrow Plans Trial of SPI-62 in Cushing’s Syndrome

295309

Sparrow Plans Trial of SPI-62 in Cushing’s Syndrome

Sparrow Pharmaceuticals is planning to launch a Phase 2 clinical trial to assess the safety and effectiveness of its investigational, lead small molecule HSD-1 inhibitor, SPI-62, in people with Cushing’s syndrome. The trial is expected to open later this year, and it specifically will enroll people with ACTH-dependent Cushing’s syndrome who also have at least one of the following conditions: type 2 diabetes, impaired glucose (blood sugar) tolerance, or hyperlipidemia (abnormally high fat levels in…

You must be logged in to read/download the full post.